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Abstract

Author Manuscript

The critical role of IgM in controlling pathogen burden has been demonstrated in a variety of
infection models. In the murine model of Borrelia hermsii infection, IgM is necessary and
sufficient for the rapid clearance of bacteremia. Convalescent, but not naïve, B1b cells generate a
specific IgM response against B. hermsii, but the mechanism of IgM-mediated protection is
unknown. Here we show that neither Fcα/μR, a high-affinity receptor for IgM, nor IgM-dependent
complement-activation are required for controlling B. hermsii. Bacteria in diffusion chambers with
a pore size impermeable to cells were killed when diffusion chambers were implanted either into
convalescent or passively immunized mice. Furthermore, adoptively transferred convalescent B1b
cells in Rag1−/− mice produced specific IgM that also cleared B. hermsii in diffusion chambers
independent of complement. These results demonstrate that IgM-mediated clearance of B. hermsii
does not require opsonophagocytosis and indicate that a mechanism for in vivo B1b cell-mediated
protection is through the generation of bactericidal IgM.
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IgM is important for the early control of infection. Natural IgM is generated spontaneously
in the absence of antigenic stimulation and can contribute to early defense by limiting the
initial pathogen burden [1, 2]. IgM is also generated in an antigen-specific manner during
the early phases of the immune response to specific pathogens. Natural IgM as well as
antigen-induced IgM have been demonstrated in protective immunity to a number of
pathogens, such as Streptococcus pneumoniae and influenza virus [3, 4].
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The vital role of IgM in the rapid control of bacteremia due to infection with relapsing fever
bacteria is well defined [5, 6]. To study the role of IgM in controlling bacteremia we have
been utilizing the murine model of infection by Borrelia hermsii, a relapsing fever spirochete
that causes recurrent episodes of high-level (~108 bacteria/ml blood) bacteremia associated
with the outgrowth of individual serotypes [7, 8]. These serotypes are defined by the
transient expression of antigenically distinct major surface proteins of B. hermsii, the
variable major proteins (Vmps) [8]. Control of each wave of bacteremia is concurrent with
the rapid production of specific IgM [9–14]. Mice that are deficient in the secreted form of
IgM – but not other isotypes – exhibit persistent bacteremia that is identical to that found in
mice that lack B cell development [14]. In contrast, mice deficient in activation-induced
cytidine deaminase – that produce only IgM but no other antibody isotypes – control
infection indistinguishably from wildtype mice [15]. These results demonstrate that IgM is
required and sufficient for the resolution of B. hermsii bacteremia.
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Concurrent with the resolution B. hermsii infection there is an expansion of B1b
lymphocytes (IgMhi, IgDlo, CD23−, CD5−, Mac1+), a minor subset of mature B cells that are
abundant in the peritoneal cavity [14, 15]. Reconstitution of immunodeficient Rag1−/− mice
(lacking T and B cells) with expanded B1b cells from convalescent mice confers complete
immunity, whereas reconstitution with naive B1b cells provides only partial protection,
demonstrating that convalescent B1b cells have acquired immunological memory [15]. Like
conventional memory B cells, the reconstituted population persists but does not
spontaneously secrete B. hermsii-specific antibodies; rather the B1b cells maintain
quiescence. Upon a subsequent exposure to antigen, however, B1b cells rapidly differentiate
into antigen-specific IgM secreting plasma cells, resulting in a specific antibody response
that is faster and of a greater magnitude than that of naïve B1b cells [15]. Although a B.
hermsii antigen recognized by B1b cell-derived IgM has been defined [15, 16], it is not clear
how B1b cell-derived IgM controls B. hermsii.

Author Manuscript

The pentameric structure of IgM is known to efficiently induce the classical complement
pathway (11). Despite this, C3–/– and C5–/– mice control relapsing fever Borrelia infection
as efficiently as wildtype mice demonstrating that antigen-specific IgM eliminates its targets
independently of complement [5, 13, 17, 18]. Although IgM is not typically known as an
opsonin, a high-affinity Fcα/μ receptor for IgM has been identified. This receptor is
expressed on macrophages and B cells as well as on non-hematopoietic tissues in organs
such as kidney and intestine [19–21]. Furthermore, Fcα/μR has been demonstrated to
facilitate the phagocytosis of IgM-coated Staphylococcus aureus in vitro, suggesting a role
for it in the clearance of IgM-coated pathogens [19]. In support of this, specific antibodycoated B. hermsii bacteria are engulfed by neutrophils in a complement-independent
manner, indicating that antibody-mediated opsonophagocytosis is a potential mechanism of
clearance of B. hermsii [22]. Nevertheless, it is unknown whether Fcα/μR-mediated
endocytosis plays a role in facilitating IgM-mediated control of B. hermsii in vivo.
In addition to promoting opsonophagocytosis and complement activation, antibodies of
various isotypes have been shown to exert direct anti-bacterial activities. These antibodies
appear to exert these effects by catalyzing the production of oxidative molecules [23–25],
interfering with pathogen iron uptake [26, 27], or by directly damaging the bacterial
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membrane [5, 18]. Among the IgM antibodies that have been described to be bactericidal,
CB515 recognizes a Vmp expressed by a Spanish relapsing fever Borrelia species, lyses
bacteria in vitro, and confers partial protection in complement-deficient mice in vivo [18].
The scFv fragments of CB515 retain the lytic activity of the parent monoclonal,
demonstrating that the bactericidal activity resides in the variable region of the antibody
[28].
In this study, we examined the mechanism of B1b cell-derived antibody in control of B.
hermsii infection in vivo. Here we show that the IgM-mediated control of B. hermsii
bacteremia is independent of Fcα/μR and C3 and does not require innate or adaptive
immune cell contact. Using a diffusion chamber model to examine host-pathogen
interactions, we demonstrate that B1b cells contribute to protective immunity by producing
B. hermsii-specific antibodies that are directly bactericidal.

Author Manuscript

Materials and Methods
Mice.
The Institutional Animal Care and Use Committee approved these studies. Mice were
housed in micro-isolator cages with free access to autoclaved food and water, and were
maintained in a specific pathogen-free facility at Thomas Jefferson University. C57BL/6J
(B6), Balb/cJ, and C57BL/6J-Rag1tm1Mom/J (Rag1–/–) mice were purchased from The
Jackson Laboratories (Bar Harbor, ME). Fcα/μR−/− mice were described previously [20].
C3-deficient mice on a C57BL6 background (C3−/−) were provided by Robert Eisenberg,
University of Pennsylvania.

Author Manuscript

Infections and cobra venom factor treatment.
Mice were infected intravenously (i.v.) via the tail vein with 5×104 bacteria of the fully
virulent B. hermsii strain DAH-p1 (from the blood of an infected mouse), and bacteremia
was monitored by dark-field microscopy. To deplete C3, mice were treated i.p. with 30 g
(14.0 units) cobra venom factor (CVF) (Quidel, San Diego, CA) one day prior to infection
and again three days post infection as described [29]. This dose of CVF is sufficient to
maintain serum C3 levels below 5% of normal levels for four days [30]. At three days postinfection, mice were treated with the same dose of CVF to maintain C3 depletion.
Passive immunizations.
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To obtain convalescent immune serum, blood was obtained via cardiac puncture from
wildtype mice that had been infected (>60 days post infection) with B. hermsii. To initiate
clotting, blood was pooled and incubated at 37°C for 1 hr. After clotting, blood was
centrifuged at 1000 x g, and serum was collected and filtered through 0.22 m PES
membranes (Millipore, Billerica, MA). Passive immunizations were performed by injecting
mice with 250 l serum via the tail vein.
Enzyme-linked immunosorbent assay (ELISA).
IgM levels were measured with ELISA kits according to the manufacturer’s instructions
(Bethyl Laboratories, Montgomery, TX). B. hermsii-specific IgM was determined by coating
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96-well plates (ICN Biomedicals Inc., Aurora, OH) with in vivo grown B. hermsii DAH (105
bacteria/well). Plates were washed and blocked with 2% BSA in PBS pH 7.2 for 2 hr at
room temperature. Blood samples of immunized mice were diluted 1:250 and samples were
centrifuged (16,000 x g for 10 min.). Bound IgM was measured using HRP-conjugated goat
anti-mouse IgM. Specific antibody levels were converted to ng/μl equivalents using IgM
standards.
Diffusion chambers.
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Mixed cellulose ester membranes (0.05 m pore size; Millipore) were adhered to lucite
diffusion chamber rings (weight - 0.4 g; diameter - 14 mm; Width - 5 mm; Millipore) as
described previously [31]. Diffusion chambers were loaded with 200 l of in vivo-adapted B.
hermsii strain DAH in BSK-H medium (Sigma-Aldrich, St. Louis, MO) supplemented with
6% rabbit serum (Sigma-Aldrich) at 6.67 × 106 bacteria/ml (1.33 × 106 bacteria per
chamber), and diffusion chambers were sealed. Mice were anesthetized with 3% isoflurane,
and using aseptic technique, diffusion chambers were implanted in a subcutaneous pocket
formed by making an incision of approximately 1.5 cm in the dorsal-anterior skin of each
mouse. Diffusion chambers were removed after 24 hours, and contents were collected.
Bacterial numbers in the chamber were measured by dark-field microscopy. Chamber
contents were stored at −20°C until analyzed. In some experiments, mice were passively
immunized with a) 250 μl convalescent immune serum or b) such serum from mice treated
with 14.0 units CVF one day prior to implantation as described above.
B1b cell reconstitution.
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Rag1–/– mice were reconstituted with 105 purified B1b cells from convalescent (i.e.,
resolved B. hermsii infection) mice as described [15]. Because Rag1–/– mice reconstituted
with convalescent B1b cells do not generate a specific IgM response without bacterial
stimulation, they were infected i.v. with 5 × 104 bacteria of the B. hermsii DAH-p1 ten days
after adoptive transfer of B1b cells.
Statistical analysis.
Statistics were performed using the Prism 5 software program (GraphPad Software, Inc., La
Jolla, CA). To analyze statistical significance, two-tailed unpaired Student’s t-test or twoway ANOVA were used as necessary.

Results
Clearance of B. hermsii does not require Fcα/μR-mediated opsonophagocytosis.

Author Manuscript

Antibody has been shown to enhance opsonophagocytosis of B. hermsii by neutrophils in
vitro [22]. Recently Fcα/μR, a specific receptor for IgM, has been shown to mediate
opsonophagocytosis of IgM-coated S. aureus [19]. Since antibodies – in particular IgM – are
critical for the protection against B. hermsii, we infected mice deficient in Fcα/μR to
examine whether Fcα/μR plays a role in IgM-mediated opsonophagocytosis. The magnitude
and duration of B. hermsii bacteremia during the first episode in these mice were
comparable to that of wildtype mice (Figure 1A). Moreover, passive immunization conferred
protection to Fcα/μR−/− mice indicating that immune serum can control B. hermsii in an
Immunol Res. Author manuscript; available in PMC 2019 August 23.
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Fcα/μR-independent manner (Figure 1B). Consistent with the critical role for IgM in control
of this bacterium, Fcα/μR−/− mice rapidly generated a B. hermsii-specific IgM response to a
similar extent as in wildtype mice (Figure 1C). Although infection with B. hermsii does
eventually elicit an IgG response, this does not occur until after the first wave of bacteremia
is cleared. Thus, the IgM-mediated clearance of the first wave does not require Fcα/μR.
Control of B. hermsii in the absence of Fcα/μR-mediated opsonophagocytosis is
independent of C3.

Author Manuscript

It is known that control of relapsing fever bacteremia occurs independently of the
complement system, as bacterial clearance occurs in the absence of C3 and C5 [13]. These
results suggest that complement either does not contribute to clearance or that other
mechanisms such as opsonophagocytosis operate in a redundant fashion. To examine
whether complement-mediated lysis or complement-mediated opsonophagocytosis plays a
critical function in the absence of Fcα/μR-mediated opsonophagocytosis, we depleted C3 in
wildtype and Fcα/μR−/− mice with cobra venom factor (CVF). Despite a deficiency in both
Fcα/μR and C3, the magnitude of the bacteremia was similar in CVF-treated and-untreated
wildtype and Fcα/μR−/− mice (Figure 2). These results indicate that the effector mechanism
of B. hermsii-specific IgM is neither C3- nor Fcα/μR-dependent.
Antibody-mediated control of B. hermsii does not require phagocytic cell contact.
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Since phagocytosis can be promoted by a variety of other mechanisms, we tested whether
IgM-mediated control of B. hermsii in vivo requires cell contact. To test this, we adapted a
diffusion chamber system originally devised to model host-pathogen interactions during
parasite infections [31]. The pore size of these diffusion chambers (0.05 m) was large
enough to allow free diffusion of IgM (300 Å) while restricting both the escape of B. hermsii
(~0.25 × ~5.0 μm) and the entrance of host cells. Each chamber contained 1.33 × 106 in
vivo-adapted B. hermsii spirochetes in bacterial growth medium. A schematic of the
diffusion chamber model is shown in Figure 3A. After 24 hours in naïve mice, the number
of bacteria in each chamber was approximately threefold higher than the initial number. In
contrast, the bacteria in diffusion chambers implanted in convalescent mice were nearly
undetectable (Figure 3B).
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The numbers of B. hermsii were also reduced significantly in diffusion chambers implanted
in passively immunized mice (Figure 3B). Interestingly, the degree of bacterial killing in
these mice was lower than what was observed in the diffusion chambers implanted in
convalescent mice, suggesting that the amount of specific IgM present in the chamber had a
direct effect on bacterial killing inside the diffusion chambers. Therefore, we examined
specific IgM levels in the diffusion chambers taken from naïve mice, convalescent mice, and
naïve mice that were given convalescent immune serum. As expected, we found that specific
IgM had entered the diffusion chambers implanted in convalescent mice and passively
immunized naïve mice. Furthermore, increasing amounts of specific IgM in each chamber
inversely correlated with bacterial viability (Figure 3C). These results demonstrate that lysis
of B. hermsii in diffusion chambers is IgM-dependent and does not require cell contact.
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As described above, IgM controls B. hermsii independent of C3 or Fcα/μR-mediated
opsonophagocytosis. To test whether cell contact-independent killing of B. hermsii in
diffusion chambers is also complement-independent, we depleted C3 in naïve and
convalescent wildtype mice with CVF one day prior to implantation of diffusion chambers.
As expected, bacterial growth was unhindered in naïve mice regardless of whether
complement was depleted (Figure 4A). In contrast, there were no bacteria remaining in
chambers removed from convalescent mice irrespective of the presence or depletion of C3
(Figure 4A).
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To confirm that IgM is bactericidal in vivo independent of the complement system, we used
mice deficient in both the alternative and classical complement pathways due to a targeted
deletion in the C3 gene. Diffusion chambers containing 1.33 × 106 B. hermsii bacteria were
implanted into convalescent wildtype and C3−/− mice. In agreement with the above results,
bacteria in diffusion chambers were killed in both wildtype and C3−/− mice (Figure 4B).
These results demonstrate that C3 is not required for antibody-mediated lysis of B. hermsii
in the diffusion chambers.
B1b cell-derived antibodies are sufficient to kill B. hermsii in diffusion chambers.

Author Manuscript

To determine whether B1b-derived IgM is capable of clearing B. hermsii independently of
opsonophagocytosis, we tested whether IgM generated by adoptively transferred
convalescent B1b cells was able to kill B. hermsii in diffusion chambers. Rag1−/− mice
reconstituted with purified convalescent B1b cells and primed with B. hermsii generated a B.
hermsii-specific IgM response (Figure 5A). To measure cell-independent killing by B1bderived IgM, we implanted diffusion chambers containing 1.33 × 106 spirochetes in
reconstituted Rag1−/− mice at ten days post-infection. As expected, B. hermsii bacteria in
diffusion chambers proliferated extensively when implanted in unreconstituted Rag1−/−
recipients. On the other hand, we observed a significant decrease in the number of live
bacteria in diffusion chambers implanted in mice reconstituted with convalescent B1b cells
(Figure 5B). These results demonstrate that IgM generated by B1b cells is directly
bactericidal in vivo.

Discussion

Author Manuscript

IgM plays a critical role in immunity to a number of infections [2]. The production of
specific IgM is required and sufficient to control bacteremia during relapsing fever infection
[14, 15]. We have previously shown that B1b cells generate B. hermsii-specific IgM that is
capable of controlling B. hermsii bacteremia. Here we show that the IgM-mediated control
of B. hermsii bacteremia is independent of Fcα/μR and C3 and does not require innate or
adaptive immune cell contact. Our data indicate that the mechanism of B1b-mediated
control of B. hermsii is through the secretion of bactericidal antibodies.
Although antibodies tend to exert their protective function through the activation of the
complement cascade or via Fc receptor engagement, some cause direct damage to pathogens
in a variety of other ways. For example, a Pseudomonas aeruginosa LPS-specific IgG alters
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cell wall permeability and causes the formation of cell wall vesicular structures, elongation,
and inhibition of cell division [32]. The bactericidal IgG CB2, specific for OspB of Borrelia
burgdorferi, induces the formation of 2.8 – 4.4 nm pores in the outer membrane of the
bacterium [33]. Paradoxically, this antibody does not induce lysis of OspB-expressing E.
coli, indicating that IgG-induced lysis is dependent on the cell membrane structure of B.
burgdorferi or the expression of another B. burgdorferi protein. In fact, the lytic activity of
CB2 depends on cholesterol domains in the outer membrane of B. burgdorferi, suggesting
that CB2 alters the fluid structure of the bacterial outer membrane [34]. In addition, B.
burgdorferi has been shown to harbor a prophage holin or holin-like system containing the
genes blyA and blyB on the conserved circular plasmid cp32 [35]. Transformation of E. coli
with blyA induces cell membrane damage that is dependent on a host cytolysin ClyA acting
in trans, demonstrating that the gene product of blyA is functional [36]. Remarkably,
treatment of B. burdgorferi spirochetes with sublethal quantities of CB2 induced the
expression of cp32 gene products BlyA and BlyB, suggesting that the bactericidal activity of
CB2 may be dependent on the induced expression of bacteriophage gene products [37].
Since bactericidal activity of the V region of an IgM specific for a Vmp expressed by a
related relapsing fever Borrelia species results in direct lysis of the bacterial outer membrane
[18], it is possible that B1b-derived IgM also kills B. hermsii in a similar fashion.
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Relapsing fever spirochetes achieve extremely high bacterial numbers (~108/ ml blood) with
in 2–3 days. In the entire body the bacterial numbers can be on the order of hundreds of
billions. Because of the bacterial tropism to blood and the high bacterial burden, the number
of phagocytic cells needed to contain the infection may not be an achievable option by the
host immune system. While complement activation could control the infection through
bacterial lysis, the amount of complement-derived split products can have a detrimental
effect on the host. Therefore the control of high bacterial burden by direct bactericidal
activity of antibodies could play a role in host defense. Our data indicate that B1b cells can
generate such an antibody response very rapidly to control B. hermsii bacteremia. Since B1b
cells have been shown to play a role in controlling a number of bacterial pathogens including
Streptococcus pneumoniae and non-typhoidal Salmonella [4, 15, 38], it is tempting to
speculate whether these pathogens are also controlled by bactericidal antibodies derived
from B1b cells.
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In the absence of all other B cell types, convalescent B1b cells are sufficient to provide
protection from B. hermsii infection in immunodeficient mice. We have shown that FhbA,
an outer surface protein of B. hermsii is specifically recognized by the IgM secreted by
convalescent B1b cells [16]. The previously described anti-Borrelia antibodies recognize
major surface bacterial proteins such as OspB and Vmps rather than FhbA. Although the
present study indicates that B1b cells secrete B. hermsii-specific IgM that is capable of
leading to direct bacterial lysis, the biochemical basis for the antibody-mediated lysis of B.
hermsii is unknown. The generation of B1b-derived monoclonal antibodies to FhbA of B.
hermsii and the characterization of such antibodies would provide a better insight on how
B1b cell-derived antibodies exert their antibacterial activity in the complete absence of a
cell-contact.
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Figure 1. Fcα/μReceptor is not required for clearance of B. hermsii.

(A). Balb/cJ or Fcα/μR−/− mice were infected i.p. with B. hermsii, and bacteremia was
monitored by dark-field microscopy of blood specimens. Each plot represents an individual
mouse. Dotted lines represent limit of detection. (B). One day prior to infection, serum from
convalescent (80 days post-infection) wildtype mice was passively transferred either into
Balb/cJ or Fcα/μR−/− mice. Bacteremia was monitored by dark-field microscopy. Dotted
lines represent the limit of detection. (C). B. hermsii-specific IgM was measured by ELISA.
Data points represent mean SD. Kinetics of anti-B. hermsii IgM responses were not
statistically significant between wildtype and Fcα/μR−/− mice.
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Figure 2. Fcα/μR- and C3-mediated opsonophagocytosis are not required for clearance of B.
hermsii.

(A) Balb/cJ or (B) Fcα/μR−/− mice were either treated or not treated with 14.0 units of cobra
venom factor (CVF) to deplete complement component C3 on the days indicated (arrows).
Mice were infected with B. hermsii, and bacteremia was monitored by dark-field
microscopy of blood. Each plot represents an individual mouse. Dotted lines represent limit
of detection.
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Figure 3. Antibody-mediated lysis in diffusion chambers.
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(A) Diffusion chamber model. B. hermsii (size: ~0.25 m × ~5.0 m) and eukaryotic cells are
unable to pass through the 0.05 m pores size membrane of the diffusion chambers. IgM can
passively diffuse through the chamber membrane. (B) Diffusion chambers containing 1.33 ×
106 B. hermsii were implanted into groups of naïve, convalescent or passively immunized
mice (n= 4–7 per group). Diffusion chambers were removed after 24 hours and live bacteria
in the diffusion chambers were enumerated by dark-field microscopy. Data represent mean ±
SD. The dotted line represents the starting number of bacteria in each chamber. Data were
analyzed by two-tailed unpaired Student’s t test, with significance reached at p < 0.05. (C)
B. hermsii-specific IgM in diffusion chambers was measured by ELISA, and specific IgM
values were matched with chamber bacterial density. Non-linear regression analysis
measuring the effect of specific IgM concentration on bacterial viability was performed.
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Figure 4. Lysis of B. hermsii in diffusion chambers is C3-independent.
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(A) Cobra venom factor (CVF, 14.0 units) was given to naïve (n=4) or convalescent (n=5)
B6 mice one day prior to implantation of diffusion chambers containing B. hermsii. Control
groups of naïve (n=3) or convalescent (n=3) mice were given Dulbecco’s phosphatebuffered saline. (B) Diffusion chambers containing 1.33 × 106 B. hermsii were implanted
into naïve B6 mice (n=4), convalescent B6 mice (n=4), or convalescent C3−/− mice (n=3).
For A and B, diffusion chambers were removed from mice after 24 hours, and bacteria in the
diffusion chambers were counted by dark-field microscopy. Mean numbers of bacteria ± SD
are shown. (N.D.–not detectable). The dotted line indicates starting number of bacteria in
each chamber. Data were analyzed by two-tailed unpaired Student’s t test, with significance
reached at p < 0.05.
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Figure 5. B1b cell-derived IgM is sufficient to kill B. hermsii in diffusion chambers.
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Rag1−/− mice were either reconstituted or not with B1b cells (105 cells per mouse) from
convalescent B6 mice. After 10 days, mice were infected with B. hermsii in order to
stimulate IgM production. (A) B. hermsii-specific IgM in non-reconstituted (n=4) or B1breconstituted mice (n=4) was determined by ELISA. Means ± SD are shown. Data were
analyzed by two-way ANOVA, with significance reached at p < 0.05. (B) On day 10 postinfection, diffusion chambers containing B. hermsii were implanted into mice from each
group. Twenty-four hours later diffusion chambers were removed, and live bacteria in the
diffusion chambers were counted by dark-field microscopy. The dotted line represents the
starting number of B. hermsii in each chamber. Data were analyzed by two-tailed unpaired
Student’s t test, with significance reached at p < 0.05.

Author Manuscript
Immunol Res. Author manuscript; available in PMC 2019 August 23.

